Biohaven earnings set to show cash burn ahead of epilepsy data

Biohaven Pharmaceutical Holding Co Ltd is set to release its second-quarter earnings report on Monday, with analysts closely monitoring the company's cash burn rate as it prepares to present crucial epilepsy drug data later this year. The biotech, operating at a loss, reported a narrowed loss of 75 cents per share for the quarter ending June, down from an 88-cent loss in the first quarter.

As of March 31, Biohaven had $351.8 million in cash and equivalents, and investors will scrutinize how swiftly the New Haven, Conn.-based company depletes this reserve. Despite a lackluster stock performance, analysts rate Biohaven as a buy with a mean price target of $22.93, suggesting a 56% upside. The company's loss is expected to decline by over 61% year-over-year, reflecting cost-cutting measures implemented in late 2025.

Biohaven's focus remains on execution and cash management rather than top-line growth, as it has not generated revenue while advancing its pipeline through clinical trials. The company announced a restructuring in November 2025 aimed at reducing annual direct R&D spend by approximately 60%, and Monday's report will reveal whether these savings are being realized.

Opakalim, Biohaven's epilepsy treatment candidate, is slated for pivotal RISE3 Phase II/III trial results in the second half of 2026, serving as the company's most significant near-term catalyst. A recent downgrade from BofA Securities to Underperform has raised concerns about opakalim's differentiating potential in the competitive epilepsy market, particularly when compared to competing treatments.